Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 31 of 41, showing 5 Applications out of 204 total, starting on record 151, ending on 155

# Protocol No Study Title Investigator(s) & Site(s)

151.

ECCT/19/04/05   PHOENIx MDR-TB
    A5300B/I2003B/PHOENIx "Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients"   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View

152.

ECCT/18/07/06   Hestia 3
    A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Prof Jessie Nyokabi Githanga
2. Videlis Nduba
3. Janet N Oyieko
4. Bernards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Chandaria Health Center Clinical Research Clinic (Nairobi City county)
3. Kenya Medical Research Institute (KEMRI) Kisumu (Kisumu county)
4. KEMRI Kombewa Clinical Research Centre (Nairobi City county)
5. Kondele Children\'s Hospital (Kisumu county)
6. Strathmore University Medical Centre (Nairobi City county)
 
View

153.

ECCT/20/11/05   HOPE Kids 2
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2)   
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. KEMRI/CRDR Clinical Research Annex (Nairobi City county)
3. Strathmore University Medical Centre (Nairobi City county)
4. KEMRI/CRDR Siaya (Siaya county)
 
View

154.

ECCT/17/09/01   HPTN 084
    HPTN 084:   A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women         
Principal Investigator(s)
1. Samuel Gurrion Ouma
Site(s) in Kenya
KISUMU CRS
 
View

155.

ECCT/17/09/02   WHO ACTION-I and ACTION-2 Trial
    A65913: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes       A65916: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes   
Principal Investigator(s)
1. Frederick Were
2. John Kinuthia
3. Zahida Parveen Qureshi
4. Zahida Parveen Qureshi
5. Zahida Parveen Qureshi
Site(s) in Kenya
1. Coast Provincial General Hospital (Mombasa Level 5 Hospital) (Mombasa county)
2. Kiambu Level 4 Hospital (Kiambu county)
3. Thika Level 5 Hospital (Kiambu county)
4. Nakuru Level 5 Hospital (Nakuru county)
 
View